Management of Crohn's Disease in Adults
暂无分享,去创建一个
S. Hanauer | W. Sandborn | G. Lichtenstein | Stephen B Hanauer | William J Sandborn | Gary R Lichtenstein
[1] Province,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[2] B. Korelitz,et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. , 1993, The American journal of gastroenterology.
[3] R. Modigliani,et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. , 2000 .
[4] B. Korelitz,et al. Narcotic dependence in inflammatory bowel disease. , 1988, Journal of clinical gastroenterology.
[5] J Y Mary,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[6] M. Bala,et al. Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries , 2004, American Journal of Gastroenterology.
[7] A. Forbes,et al. the risks of malignancy from either immuno‐suppression or diagnostic radiation in inflammatory bowel disease , 1995 .
[8] Alphonso Brown,et al. The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease , 2006, The American Journal of Gastroenterology.
[9] B. Feagan. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. , 2003, The European journal of surgery = Acta chirurgica.
[10] S. Schreiber,et al. Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.
[11] J. Mary,et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease , 1999, American Journal of Gastroenterology.
[12] M. Keighley,et al. Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis. , 1999, Scandinavian journal of gastroenterology.
[13] M. Cheang,et al. A Population-Based Case Control Study of Potential Risk Factors for IBD , 2006, The American Journal of Gastroenterology.
[14] P. Gibson,et al. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: Safe alternative to surgery , 2007, Journal of gastroenterology and hepatology.
[15] A. Ekbom. Risk Factors and Distinguishing Features of Cancer in IBD , 1998, Inflammatory bowel diseases.
[16] Amy K Hara,et al. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. , 2006, Radiology.
[17] J. Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.
[18] R. Baldassano,et al. Nutrition and inflammatory bowel disease. , 1999, Gastroenterology clinics of North America.
[19] R. Thisted,et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.
[20] M. Rutter,et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] R. Woods,et al. Anal pathology in patients with Crohn's disease. , 1996, The Australian and New Zealand journal of surgery.
[22] G. Greenberg,et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.
[23] D. Present,et al. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. , 2005, Inflammatory bowel diseases.
[24] K. Gardiner,et al. Operative management of small bowel Crohn's disease. , 2007, The Surgical clinics of North America.
[25] J. Markowitz,et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.
[26] G. Costamagna,et al. Video Capsule Endoscopy in Patients With Known or Suspected Small Bowel Stricture Previously Tested With the Dissolving Patency Capsule , 2007, Journal of clinical gastroenterology.
[27] Z. Fireman,et al. Cyclosporin for severe ulcerative colitis. , 2000, The Israel Medical Association journal : IMAJ.
[28] J. Belaiche,et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.
[29] S. Targan,et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.
[30] S. Travis,et al. Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.
[31] M. Regueiro,et al. Infliximab for Prevention of Crohnʼs Disease (CD) Recurrence after Ileal Resection: 1054 , 2008 .
[32] M. Dubinsky,et al. A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine , 2005, The American Journal of Gastroenterology.
[33] M. Kamm,et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.
[34] A. Steinhart,et al. Budesonide for maintenance of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.
[35] C. Lamers,et al. Proximal Crohn's Disease: Review of the Clinicopathologic Features and Therapy , 2001, Inflammatory bowel diseases.
[36] S. Hanauer,et al. AGA technical review on perianal Crohn's disease. , 2003, Gastroenterology.
[37] J. Belaiche,et al. Clinical pattern of corticosteroid dependent Crohn's disease , 1998, European journal of gastroenterology & hepatology.
[38] K. Kip,et al. Crohn's Disease: A Two-Year Prospective Study of the Association Between Psychological Distress and Disease Activity , 2004, Digestive Diseases and Sciences.
[39] B. Korelitz,et al. Intravenous Corticotrophin vs. Hydrocortisone in the Treatment of Hospitalized Patients with Crohn's Disease: A Randomized Double‐Blind Study and Follow‐Up , 1998, Inflammatory bowel diseases.
[40] S. Fredd. Standards for Approval of New Drugs for IBD , 1995, Inflammatory bowel diseases.
[41] A. Pisani,et al. Oral tacrolimus long‐term therapy in patients with Crohn’s disease and steroid resistance , 2001, Alimentary pharmacology & therapeutics.
[42] P. Rutgeerts,et al. Review article: altering the natural history of Crohn's disease – evidence for and against current therapies , 2006, Alimentary pharmacology & therapeutics.
[43] A. Griffiths,et al. Enteral nutritional therapy for inducing remission of Crohn's disease. , 2001, The Cochrane database of systematic reviews.
[44] R. Sartor,et al. Treatment of inflammatory bowel disease with antibiotics. , 2004, Gastroenterology clinics of North America.
[45] E. Loftus. Management of extraintestinal manifestations and other complications of inflammatory bowel disease , 2004, Current gastroenterology reports.
[46] A. Griffiths,et al. Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.
[47] P. Rutgeerts,et al. Optimizing anti-TNF treatment in inflammatory bowel disease. , 2004, Gastroenterology.
[48] R. Maunder. Evidence that Stress Contributes to Inflammatory Bowel Disease: Evaluation, Synthesis, and Future Directions , 2005, Inflammatory bowel diseases.
[49] A. Zinsmeister,et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. , 2002, Gastroenterology.
[50] S. Targan,et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.
[51] A. Griffiths,et al. Corticosteroids for maintenance of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.
[52] G. Greenberg,et al. Oral Budesonide for Active Crohn's Disease , 1994 .
[53] L. Guidi,et al. Clinical correlations of small bowel CT and contrast radiology findings in Crohn's disease. , 2004, European review for medical and pharmacological sciences.
[54] L. Brandt,et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. , 1982, Gastroenterology.
[55] B. Kirschner. Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. , 1998, The Netherlands journal of medicine.
[56] M. Kristensen,et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. , 1974, Scandinavian journal of gastroenterology.
[57] M. Stolte,et al. High incidence of upper gastrointestinal tract involvement in Crohn’s disease , 1998, Virchows Archiv.
[58] K. Carroll. 3 Crohn's disease: new imaging techniques , 1998 .
[59] J. Geoghegan,et al. Fulminant colitis in inflammatory bowel disease , 1998, Diseases of the colon and rectum.
[60] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[61] A. Laupacis,et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. , 1994, The New England journal of medicine.
[62] J. Kremer,et al. Methotrexate for Rheumatoid Arthritis , 1994 .
[63] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[64] D. Jewell,et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. , 1998, The New England journal of medicine.
[65] W. Sandborn. Azathioprine: state of the art in inflammatory bowel disease. , 1998, Scandinavian journal of gastroenterology. Supplement.
[66] V. Fazio,et al. Evolution of surgery for Crohn's disease , 1999, Diseases of the colon and rectum.
[67] D. Jewell,et al. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease , 1998 .
[68] D. Rockey,et al. Noninvasive measures of liver fibrosis , 2006, Hepatology.
[69] J. Rhodes,et al. 10 Adjuvant post-operative therapy , 1998 .
[70] A. Zinsmeister,et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. , 1994, Journal of clinical gastroenterology.
[71] E. Irvine. Quality of life issues in patients with inflammatory bowel disease. , 1997, The American journal of gastroenterology.
[72] S. Hanauer,et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.
[73] F. Tonelli,et al. [Colorectal Crohn's disease: indications to surgical treatment]. , 2003, Annali italiani di chirurgia.
[74] H. Steinhart,et al. Combination ciprofloxacin and metronidazole for active Crohn's disease. , 1998, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[75] B. Bonaz,et al. 6‐Tioguanine monitoring in steroid‐dependent patients with inflammatory bowel diseases receiving azathioprine , 2005, Alimentary pharmacology & therapeutics.
[76] G. Thomas,et al. Inflammatory Bowel Disease and Smoking—A Review , 1998, American Journal of Gastroenterology.
[77] M. Campieri,et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease , 1997, Gut.
[78] D. Jewell,et al. A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.
[79] A. Mee,et al. Omeprazole in possible esophageal Crohn's disease , 1994, Digestive Diseases and Sciences.
[80] Irvine Ej. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. , 1995 .
[81] D. Jewell,et al. Preventing postoperative recurrence of Crohn's disease , 1997, The British journal of surgery.
[82] K. Bodger,et al. Clinical economics review: medical management of inflammatory bowel disease , 1999, Alimentary pharmacology & therapeutics.
[83] B. Kirschner,et al. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. , 1998, Gastroenterology.
[84] B. Kirschner,et al. Workshop Report: Prevention of Postoperative Recurrence in Crohn's Disease , 2005, Journal of pediatric gastroenterology and nutrition.
[85] J. Koval,et al. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. , 1996, Gastroenterology.
[86] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.
[87] G. Guyatt,et al. A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.
[88] G. Greenberg,et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. , 2000, The New England journal of medicine.
[89] J. Belaiche,et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. , 1996, Gastroenterology.
[90] F. Barkhof,et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.
[91] R. Thirlby,et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. , 1998, Archives of surgery.
[92] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[93] D. Rampton,et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool , 2004, European journal of gastroenterology & hepatology.
[94] D. Furst,et al. Safety of tumour necrosis factor-alpha antagonists. , 2004, Drug safety.
[95] W. Petritsch,et al. 6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party , 2006, Digestion.
[96] J. Becker. Surgical therapy for ulcerative colitis and Crohn's disease. , 1999, Gastroenterology clinics of North America.
[97] A. Zinsmeister,et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. , 2002, Gastroenterology.
[98] D. Symmons,et al. Systematic review: is ingestion of paracetamol or non‐steroidal anti‐inflammatory drugs associated with exacerbations of inflammatory bowel disease? , 2004, Alimentary pharmacology & therapeutics.
[99] S. Hanauer,et al. Cyclosporin for severe ulcerative colitis: a user's guide. , 1997, The American journal of gastroenterology.
[100] M. Riccioni,et al. Patients With Known Small Bowel Stricture or With Symptoms of Small Bowel Obstruction Secondary to Crohn's Disease Should Not Perform Video Capsule Endoscopy Without Being Previously Tested for Small Bowel Patency , 2007, The American Journal of Gastroenterology.
[101] C. Bernstein,et al. Selected summary: Feagan BG, McDonald JWD, Rochon J, et al. for the Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846–1851 (June) , 1995 .
[102] D. Drossman,et al. Psychosocial factors in inflammatory bowel disease. , 1995, Gastroenterology clinics of North America.
[103] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[104] G. Greenberg,et al. Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials , 2005, The American Journal of Gastroenterology.
[105] W. Sandborn. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease , 2003, Current gastroenterology reports.
[106] G. Greenberg,et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. , 1996, Gastroenterology.
[107] C. Prantera,et al. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. , 1998, Italian journal of gastroenterology and hepatology.
[108] R. Modigliani,et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.
[109] H. Drummond,et al. Infliximab use in Crohn's disease: impact on health care resources in the UK , 2005, European journal of gastroenterology & hepatology.
[110] A. Griffiths,et al. Budesonide for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.
[111] W. Mow,et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[112] C. Fiocchi. Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.
[113] P. Munkholm,et al. Intestinal and extra‐intestinal cancer in Crohn's disease: follow‐up of a population‐based cohort in Copenhagen County, Denmark , 2004, Alimentary pharmacology & therapeutics.
[114] P. Schoenfeld,et al. Systematic review: the effectiveness of budesonide therapy for Crohn's disease , 2002 .
[115] W. Sandborn,et al. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. , 2004, Gastroenterology.
[116] K. Ewe,et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease , 1998 .
[117] D. Jewell,et al. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. , 1986, Journal of clinical gastroenterology.
[118] D. Franchimont,et al. Crohn's Disease , 1976, The Lancet.
[119] C. Bernstein,et al. Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.
[120] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[121] W. Sandborn,et al. Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine , 1998, American Journal of Gastroenterology.
[122] D. Macintosh,et al. Anti-tuberculous therapy for maintaining remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.
[123] K. Ewe,et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. , 1998, Gut.
[124] H. Verspaget,et al. Crohn's disease of the upper gastrointestinal tract: the value of endoscopic examination. , 1998, Scandinavian journal of gastroenterology. Supplement.
[125] P. Rutgeerts,et al. Randomized , Placebo-Controlled Trial of Certolizumab Pegol CDP 870 ) for Treatment of Crohn ’ s Disease , 2005 .
[126] W. Sandborn,et al. Practice guidelines for inflammatory bowel disease: an instrument for assessment. , 1999, Mayo Clinic proceedings.
[127] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[128] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[129] P. Hahn,et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. , 2002, Radiology.
[130] F. Shanahan. Antibody 'markers' in Crohn's disease: opportunity or overstatement? , 1997, Gut.
[131] G. Porro,et al. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role , 2000, American Journal of Gastroenterology.
[132] J. Platt,et al. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease , 2007, Inflammatory bowel diseases.
[133] B F Warren,et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis , 2006, Gut.
[134] S. Kane,et al. Tobacco Use Is Associated With Accelerated Clinical Recurrence of Crohn's Disease After Surgically Induced Remission , 2005, Journal of clinical gastroenterology.
[135] W. Reinisch,et al. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. , 1998, Wiener klinische Wochenschrift.
[136] A. Taschieri,et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. , 2004, Gastroenterology.
[137] R. Cully,et al. Weekly clinicopathological exercises. , 1990, The New England journal of medicine.
[138] R. Löfberg,et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. , 1998, Gastroenterology.
[139] S. Hanauer,et al. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[140] H. Buhr,et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. , 1999, European journal of gastroenterology & hepatology.
[141] P. Rutgeerts,et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.
[142] P. Nyström,et al. Low symptomatic load in Crohn's disease with surgery and medicine as complementary treatments. , 1998, Scandinavian journal of gastroenterology.
[143] H. V. van Lier,et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. , 1991, Annals of internal medicine.
[144] S. Vermeire. NOD2/CARD15: relevance in clinical practice. , 2004, Best practice & research. Clinical gastroenterology.
[145] P. Miner. Factors influencing the relapse of patients with inflammatory bowel disease. , 1997, The American journal of gastroenterology.
[146] P. Rutgeerts,et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.
[147] H. Verspaget,et al. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. , 1997, The American journal of gastroenterology.
[148] R. Valori,et al. Omeprazole for duodenal ulceration in Crohn's disease. , 1990, BMJ.
[149] G. Ballantyne,et al. Treatment of Crohn's colitis. Segmental or total colectomy? , 1988, Archives of surgery.
[150] A. Zinsmeister,et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.
[151] E. Vasiliauskas,et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.
[152] G. Arnold,et al. Preliminary Study of Ciprofloxacin in Active Crohn's Disease , 2002, Inflammatory bowel diseases.
[153] J. Askling,et al. Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics , 2006, Cancer Epidemiology Biomarkers & Prevention.
[154] W. Sandborn. Serologic markers in inflammatory bowel disease: state of the art. , 2004, Reviews in gastroenterological disorders.
[155] S. Targan,et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.
[156] R. Ricketts. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study , 1996 .
[157] D. Jewell,et al. A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.
[158] G. Porro,et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. , 1999, Gastroenterology.
[159] J. Lewis,et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.
[160] J. Lewis,et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. , 2003, Gastroenterology.
[161] R. Logan. Inflammatory bowel disease incidence: up, down or unchanged? , 1998, Gut.
[162] P. Rutgeerts. Review article: treatment of perianal fistulizing Crohn's disease. , 2004, Alimentary pharmacology & therapeutics.
[163] Clifford Goodman,et al. The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.
[164] J. Schwartz,et al. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. , 2000, Gastroenterology.
[165] J. Singleton. Second trial of mesalamine therapy in the treatment of active Crohn's disease. , 1994, Gastroenterology.
[166] S. Hanauer,et al. Efficacy of parenteral methotrexate in refractory Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.
[167] A. Lavy,et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. , 1998, Gastroenterology.
[168] J. Paris,et al. Maladie de Crohn jéjuno-iléale diffuse : une forme particulière de la maladie ? , 1999 .
[169] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[170] A. Osadchy,et al. Computed tomographic findings of abdominal complications of Crohn's disease--pictorial essay. , 2005, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.
[171] S. Targan,et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. , 1998, Gastroenterology.
[172] R. Modigliani,et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. , 1995, Gastroenterology.
[173] H. Freeman. Long-term clinical behavior of jejunoileal involvement in Crohn's disease. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[174] W. Sandborn,et al. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. , 1996, Mayo Clinic proceedings.
[175] A. Forbes,et al. Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. , 1995, Alimentary pharmacology & therapeutics.
[176] P. Martreau. [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.
[177] P. Rutgeerts,et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.
[178] D. Brenner,et al. Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.
[179] W. Petritsch,et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. , 2000, Gastroenterology.
[180] A. Zinsmeister,et al. Erratum: Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival (Gastroenterology (1998) 114 (1161- 1168)) , 1999 .
[181] G. Ginsberg,et al. Imaging modalities in inflammatory bowel disease. , 1999, Gastroenterology clinics of North America.
[182] K. Turetschek,et al. Crohn's disease: current imaging approach , 1998, Der Radiologe.
[183] R. Baldassano,et al. Crohn's Jejunoileitis: The Pediatrician's Perspective on Diagnosis and Management , 2005, Inflammatory bowel diseases.
[184] A. Zinsmeister,et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. , 1999, Gastroenterology.
[185] C. Brensinger,et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.
[186] R. Macdermott. Lack of current clinical value of serological testing in the evaluation of patients with IBD. , 1999, Inflammatory bowel diseases.
[187] S. Meltzer,et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. , 1986, Gastroenterology.
[188] J. Kremer,et al. Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity , 1994 .
[189] W. Leslie,et al. AGA technical review on osteoporosis in gastrointestinal diseases. , 2003, Gastroenterology.
[190] S. Hanauer,et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. , 1991, Gut.
[191] P. Munkholm,et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. , 1997, Scandinavian journal of gastroenterology.
[192] S. Schreiber. Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.
[193] G. Olaison,et al. Segmental Resection or Subtotal Colectomy in Crohn’s Colitis? , 2002, Diseases of the colon and rectum.
[194] R S Fisher,et al. Differentiation between Crohn's disease and ulcerative colitis. , 1994, The Medical clinics of North America.
[195] P. Rutgeerts. An historical overview of the treatment of Crohn's disease: why do we need biological therapies? , 2004, Reviews in gastroenterological disorders.
[196] M. Schuster,et al. Metronidazole therapy for Crohn's disease and associated fistulae. , 1984, The American journal of gastroenterology.
[197] S. Hanauer,et al. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. , 1993, The American journal of gastroenterology.
[198] D. Jewell,et al. Cyclosporine for induction of remission in Crohn's disease. , 2005, The Cochrane database of systematic reviews.
[199] P. Rutgeerts,et al. Methotrexate in refractory Crohn's disease. , 1999, Inflammatory bowel diseases.
[200] W. Selby,et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. , 2007, Gastroenterology.
[201] S. Desideri,et al. Omeprazole for peptic ulcer in Crohn's disease. , 1991, The American journal of gastroenterology.
[202] S. Strong. Prognostic parameters of Crohn's disease recurrence. , 1998, Bailliere's clinical gastroenterology.
[203] S. Targan,et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.
[204] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[205] Y. Yazdanpanah,et al. Impact of surgery on quality of life in Crohn's disease. , 1997, The American journal of gastroenterology.
[206] R. Farmer,et al. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. , 1985, Gastroenterology.
[207] W. Sandborn. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. , 1997, The American journal of gastroenterology.
[208] J. Markowitz,et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. , 1985, Gastroenterology.
[209] R Eliakim,et al. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease--final report. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[210] P. Rutgeerts,et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease , 2001, Gut.
[211] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[212] S. Hanauer,et al. Management of Crohn's disease in adults , 2001, American Journal of Gastroenterology.
[213] E. Irvine. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. , 1995, Journal of clinical gastroenterology.
[214] M. Kamm,et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.
[215] D. Crosby,et al. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial. , 1978, Gut.
[216] C. Hassan,et al. Systematic review: endoscopic dilatation in Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.
[217] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[218] M. Bala,et al. Annual cost of care for Crohn's disease: a payor perspective. , 2000 .
[219] H. Verspaget,et al. Crohn's disease of the upper gastrointestinal tract. , 1997, The Netherlands journal of medicine.
[220] C. Prantera,et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. , 1994, The American journal of gastroenterology.
[221] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[222] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[223] G. T. ten Velde,et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. , 1981, Gut.
[224] P. Prior,et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. , 1994, Gut.
[225] R. Modigliani,et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.
[226] J. Stein,et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine , 2004, Alimentary pharmacology & therapeutics.
[227] J. Schölmerich. Klinische Wirkung der verschiedenen Budesonid-Präparationen bei Morbus Crohn , 1999, Medizinische Klinik.
[228] The role of colonoscopy in the management of patients with inflammatory bowel disease. American Society for Gastrointestinal Endoscopy. , 1998, Gastrointestinal endoscopy.
[229] P. Munkholm,et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.
[230] D. Baker. Natalizumab: overview of its pharmacology and safety. , 2007, Reviews in gastroenterological disorders.
[231] G. Lichtenstein,et al. Review article: monitoring of immunomodulators in inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.
[232] J. Macdonald,et al. Natalizumab for induction of remission in Crohn's disease. , 2007, The Cochrane database of systematic reviews.
[233] Doe,et al. Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study , 1998, Alimentary pharmacology & therapeutics.
[234] R. Modigliani,et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity , 2000, American Journal of Gastroenterology.
[235] L. Ryner,et al. A Prospective Comparison Study of MRI versus Small Bowel Follow-Through in Recurrent Crohn's Disease , 2005, The American Journal of Gastroenterology.
[236] G. D'Haens,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .
[237] T. Judge,et al. Extraintestinal manifestations of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.
[238] J. Belaiche,et al. Corticosteroid treatment in active Crohn's disease. , 1998, Acta gastro-enterologica Belgica.
[239] P. Rutgeerts,et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease , 2005, Current medical research and opinion.
[240] P. Rutgeerts,et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.
[241] W. C. Tan,et al. Diffuse jejunoileitis of Crohn's disease. , 1993, Gut.
[242] P. Rutgeerts,et al. Safety issues with biological therapies for inflammatory bowel disease , 2006, Current opinion in gastroenterology.
[243] J. Goldblum,et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. , 1996, Annals of surgery.
[244] S. Hanauer,et al. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.
[245] P. Rutgeerts,et al. O08 Concomitant Immunosuppression Does Not Impact on the Outcome Of Maintenance Infliximab Therapy in Crohn's Disease: Final Results of the Imid Trial , 2007 .
[246] O. Zmora,et al. Risk Factors Regarding the Need for a Second Operation in Patients with Crohn’s Disease , 2005, Digestion.
[247] D. Present,et al. Efficacy of cyclosporine in treatment of fistula of crohn's disease , 1994, Digestive Diseases and Sciences.
[248] L. Bergman,et al. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. , 1976, Scandinavian journal of gastroenterology.
[249] J. Rhodes,et al. Adjuvant post-operative therapy. , 1998, Bailliere's clinical gastroenterology.
[250] A. Aschoff,et al. MRI in the diagnosis of small bowel disease: use of positive and negative oral contrast media in combination with enteroclysis , 2000, European Radiology.
[251] G. Fick,et al. Azathioprine for maintaining remission of Crohn's disease. , 1998, The Cochrane database of systematic reviews.
[252] B. Huitfeldt,et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. , 1982, Gastroenterology.
[253] S. Plevy. Do Serological Markers and Cytokines Determine the Indeterminate? , 2004, Journal of clinical gastroenterology.
[254] G. D'Haens,et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. , 1999, Gastroenterology.
[255] Loyd,et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.
[256] A. Zinsmeister,et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. , 1998, Gastroenterology.
[257] M. Daperno,et al. Review article: Crohn's disease: monitoring disease activity. , 2003, Alimentary pharmacology & therapeutics.
[258] B. Korelitz,et al. The safety of corticosteroid therapy in Crohn's disease with an abdominal mass. , 1991, The American journal of gastroenterology.
[259] A. Darzi,et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a metaanalysis , 2006, Surgical Endoscopy And Other Interventional Techniques.
[260] M. Vatn,et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. , 1997, Scandinavian journal of gastroenterology.
[261] H. Tilg,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.
[262] D. Jewell,et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. , 1999, Gastroenterology.
[263] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[264] R. Modigliani,et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.
[265] P. Blichfeldt,et al. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. , 1978, Scandinavian journal of gastroenterology.
[266] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[267] B. Sandstedt,et al. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. , 1994, Scandinavian journal of gastroenterology.
[268] R. Allan,et al. Segmental colonic resection is an appropriate operation for short skip lesions due to Crohn's disease in the colon , 1989, World Journal of Surgery.
[269] L. W. Ottinger,et al. Case 10-1996 , 1996 .
[270] I. Shafran,et al. An open-label evaluation of rifaximin in the treatment of active Crohn's disease* , 2005, Current medical research and opinion.
[271] J. Fontcuberta,et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease , 1995, Digestive Diseases and Sciences.
[272] C. Bernstein,et al. A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease. , 1997, Gastroenterology.
[273] A. Cohen,et al. A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease , 2008 .
[274] S. Steele. Operative management of Crohn's disease of the colon including anorectal disease. , 2007, The Surgical clinics of North America.
[275] G. Radford-Smith,et al. Chronic narcotic use in inflammatory bowel disease patients: Prevalence and clinical characteristics , 2001, Journal of gastroenterology and hepatology.
[276] J. Crowe,et al. Controlled trial of antimycobacterial therapy in Crohn's disease , 1991, Digestive diseases and sciences.
[277] S. Targan,et al. Biologic therapy of inflammatory bowel disease. , 2002, Gastroenterology.
[278] J. García,et al. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. , 2001 .
[279] W. Cooke,et al. Diffuse jejuno-ileitis of Crohn's disease. , 1974, The Quarterly journal of medicine.
[280] S. Hanauer,et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.
[281] D. Jewell,et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. , 1996, Gut.
[282] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[283] M. Neurath,et al. Anti-TNF strategies in stenosing and fistulizing Crohn’s disease , 2004, International Journal of Colorectal Disease.
[284] R. Modigliani,et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.
[285] M. Zalis,et al. Imaging of Inflammatory Bowel Disease: CT and MR , 2004, Digestive Diseases.
[286] D. Binion,et al. Narcotic use in patients with Crohn's disease , 2003, American Journal of Gastroenterology.
[287] P. Rutgeerts,et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.
[288] A. Kornbluth,et al. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. , 1995, Journal of clinical gastroenterology.
[289] B. Sands. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. , 2004, Gastroenterology.
[290] J. Dickinson,et al. Is omeprazole helpful in inflammatory bowel disease? , 1994, Journal of clinical gastroenterology.
[291] S. Schoenberg,et al. Crohn disease of the small bowel proximal to the terminal ileum: detection by MR‐enteroclysis , 2004, Scandinavian journal of gastroenterology.
[292] S. Hanauer,et al. Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial , 2005, Alimentary pharmacology & therapeutics.
[293] B. Huitfeldt,et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. , 1982, Gastroenterology.
[294] Sandborn Wj. Azathioprine: State of the Art in Inflammatory Bowel Disease , 1998 .
[295] K. Fellermann,et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) , 1998, American Journal of Gastroenterology.
[296] C. Herfarth,et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. , 1989, Digestion.
[297] R. Scully,et al. Case records of the Massachusetts General Hospital. , 1990 .
[298] D. Hommes,et al. Review article: thiopurines in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.
[299] D. Present,et al. Fistula response to methotrexate in Crohn's disease: a case series , 2003, Alimentary pharmacology & therapeutics.
[300] A. Griffiths,et al. Corticosteroids for maintaining remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.
[301] M. Campieri,et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo‐controlled trial with rifaximin , 2006, Alimentary pharmacology & therapeutics.
[302] Z. Cohen,et al. Combination of Ciprofloxacin and Metronidazole in Severe Perianal Crohn’s Disease , 1993 .
[303] J. Lennard-jones,et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease , 1985, Diseases of the colon and rectum.
[304] A. Forbes,et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.
[305] S. Hanauer,et al. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. , 1998, Clinical therapeutics.
[306] M. Cottone,et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. , 1997, Gastroenterology.
[307] B. Feagan,et al. Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.
[308] C. Bernstein,et al. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity , 1994, Digestive Diseases and Sciences.
[309] B. Feagan,et al. Methotrexate for induction of remission in refractory Crohn's disease. , 2003, The Cochrane database of systematic reviews.
[310] P. Munkholm,et al. Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.
[311] A. Cohen,et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. , 2001, Gastroenterology.
[312] J. Mate,et al. Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine , 2003, Leukemia & lymphoma.
[313] P. Rutgeerts,et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. , 2005, Gastroenterology.
[314] W. Tremaine. Gastroduodenal Crohn's disease: medical management. , 2003, Inflammatory bowel diseases.